Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial.

Saved in:
Bibliographic Details
Title: Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial.
Authors: van der Wilk BJ; Department of Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands. Electronic address: b.vanderwilk@erasmusmc.nl., Eyck BM; Department of Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., Wijnhoven BPL; Department of Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., Lagarde SM; Department of Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., Rosman C; Department of Surgery, Radboud University Medical Centre, Nijmegen, Netherlands., Noordman BJ; Department of Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., Valkema MJ; Department of Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., Bisseling TM; Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, Netherlands., Coene PLO; Department of Surgery, Maasstad Hospital, Rotterdam, Netherlands., van Det MJ; Department of Surgery, ZGT Hospital, Almelo, Netherlands., Dekker JWT; Department of Surgery, Reinier de Graaf Gasthuis, Delft, Netherlands., van Dieren JM; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Doukas M; Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., van Esser S; Department of Surgery, Reinier de Graaf Gasthuis, Delft, Netherlands., Fiets WE; Department of Medical Oncology, Medical Centre Leeuwarden, Leeuwarden, Netherlands., Hartgrink HH; Department of Surgery, Leiden University Medical Centre, Leiden, Netherlands., Heisterkamp J; Department of Surgery, Elisabeth Tweesteden Hospital, Tilburg, Netherlands., Holster IL; Department of Gastroenterology, Maasstad Hospital, Rotterdam, Netherlands., Klarenbeek B; Department of Surgery, Radboud University Medical Centre, Nijmegen, Netherlands., van Klaveren D; Department of Public Health, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., Kouw E; Department of Gastroenterology and Hepatology, Gelre Hospital, Apeldoorn, Netherlands., Kouwenhoven EA; Department of Surgery, ZGT Hospital, Almelo, Netherlands., Luyer MD; Department of Surgery, Catharina Hospital, Eindhoven, Netherlands., Mostert B; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., Nieuwenhuijzen GAP; Department of Surgery, Catharina Hospital, Eindhoven, Netherlands., Oostenbrug LE; Department of Gastroenterology and Hepatology, Heerlen, Netherlands., Pierie JP; Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, Netherlands., van Sandick JW; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Sosef MN; Department of Surgery, Zuyderland Medical Centre, Heerlen, Netherlands., Spaander MCW; Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., Valkema R; Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands., van der Zaag ES; Department of Surgery, Gelre Hospital, Apeldoorn, Netherlands., Steyerberg EW; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, Netherlands., van Lanschot JJB; Department of Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, Netherlands.
Corporate Authors: SANO Study Group
Source: The Lancet. Oncology [Lancet Oncol] 2025 Apr; Vol. 26 (4), pp. 425-436. Date of Electronic Publication: 2025 Mar 17.
Publication Type: Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(25)00027-0